JPWO2020033019A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033019A5 JPWO2020033019A5 JP2021509963A JP2021509963A JPWO2020033019A5 JP WO2020033019 A5 JPWO2020033019 A5 JP WO2020033019A5 JP 2021509963 A JP2021509963 A JP 2021509963A JP 2021509963 A JP2021509963 A JP 2021509963A JP WO2020033019 A5 JPWO2020033019 A5 JP WO2020033019A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- subject
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 229960003105 Metformin Drugs 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100007163 SLC16A3 Human genes 0.000 claims 1
- 101710032195 SLC16A3 Proteins 0.000 claims 1
- 101710032196 SLC16A4 Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
Claims (9)
- X及びYがフッ素である、請求項1に記載の医薬組成物。
- 経口又は非経口の投与用に設計されるか又は製剤化されている、請求項1又は2に記載の医薬組成物。
- MCT4を発現するがんを治療するために、それを必要とする対象に投与するための使用のための、請求項1~3のいずれか一項に記載の医薬組成物。
- 治療有効量のメトホルミンとともに前記対象に投与するための使用のための、請求項4に記載の医薬組成物。
- 前記対象がヒトである、請求項4又は5に記載の医薬組成物。
- 前記がんが、癌腫、肉腫、神経新生物、リンパ腫、骨髄腫、白血病、黒色腫、中皮腫、固形がん又は軟部組織腫瘍である、請求項4~6のいずれか一項に記載の医薬組成物。
- 前記がんが乳癌である、請求項4~7のいずれか一項に記載の医薬組成物。
- 請求項1~8のいずれか一項に記載の組成物を備える、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662637P | 2018-04-25 | 2018-04-25 | |
US62/662,637 | 2018-04-25 | ||
PCT/US2019/029192 WO2020033019A2 (en) | 2018-04-25 | 2019-04-25 | Novel mct4 inhibitors and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021522345A JP2021522345A (ja) | 2021-08-30 |
JPWO2020033019A5 true JPWO2020033019A5 (ja) | 2022-04-28 |
JP7115671B2 JP7115671B2 (ja) | 2022-08-09 |
Family
ID=68532786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021509963A Active JP7115671B2 (ja) | 2018-04-25 | 2019-04-25 | 新規なmct4阻害剤及びその使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10919878B2 (ja) |
EP (1) | EP3784650B1 (ja) |
JP (1) | JP7115671B2 (ja) |
CN (1) | CN112888673B (ja) |
AU (1) | AU2019317518B2 (ja) |
CA (1) | CA3098189A1 (ja) |
WO (1) | WO2020033019A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220075344A (ko) * | 2019-09-05 | 2022-06-08 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 미토콘드리아 기능을 변형시키는 방법 및 화합물 |
WO2021249969A1 (en) * | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
WO2022243574A1 (en) | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use |
WO2022243573A1 (en) | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1226438A (ja) * | 1968-12-03 | 1971-03-31 | ||
GB0327734D0 (en) * | 2003-11-28 | 2003-12-31 | Novartis Ag | Organic compounds |
TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
WO2010089580A1 (en) * | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
CN102731413A (zh) * | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | 一种脲类化合物、其制备方法、其中间体及其应用 |
CN105263484B (zh) * | 2013-05-24 | 2018-08-03 | 株式会社加龄.营养研究所 | 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途 |
WO2016081464A1 (en) * | 2014-11-17 | 2016-05-26 | Nirogyone Therapeutics, Inc. | Monocarboxylate transport modulators and uses thereof |
WO2016118822A1 (en) * | 2015-01-22 | 2016-07-28 | The Scripps Research Institute | Chromenone inhibitors of monocarboxylate transporters |
EP3247361A4 (en) * | 2015-01-22 | 2018-08-15 | The Scripps Research Institute | Pteridine dione monocarboxylate transporter inhibitors |
JP6944442B2 (ja) * | 2015-06-12 | 2021-10-06 | ベットーレ リミテッド ライアビリティー カンパニーVettore, Llc | 疾患を治療するためのmct4阻害剤 |
CN108368060B (zh) * | 2017-12-21 | 2020-09-15 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
-
2019
- 2019-04-25 WO PCT/US2019/029192 patent/WO2020033019A2/en unknown
- 2019-04-25 US US16/395,099 patent/US10919878B2/en active Active
- 2019-04-25 CA CA3098189A patent/CA3098189A1/en active Pending
- 2019-04-25 JP JP2021509963A patent/JP7115671B2/ja active Active
- 2019-04-25 CN CN201980035699.6A patent/CN112888673B/zh active Active
- 2019-04-25 EP EP19847325.8A patent/EP3784650B1/en active Active
- 2019-04-25 AU AU2019317518A patent/AU2019317518B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008521928A5 (ja) | ||
JP2019503365A5 (ja) | ||
RU2016141934A (ru) | Ингибиторы циклин-зависимой киназы 7 (cdk7) | |
JP2021063088A5 (ja) | ||
JP2016518437A5 (ja) | ||
JP2012082234A5 (ja) | ||
JP2020531463A5 (ja) | ||
JPWO2020033019A5 (ja) | ||
US10561647B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
JPWO2020131674A5 (ja) | ||
JP2017039714A5 (ja) | ||
JP2018140987A5 (ja) | ||
JP2021503451A5 (ja) | ||
JP2019517474A5 (ja) | ||
JP2013523867A5 (ja) | ||
JP2008546777A5 (ja) | ||
JP2020506886A5 (ja) | ||
MX2023004085A (es) | Metodos para el tratamiento del cáncer. | |
JPWO2019232257A5 (ja) | ||
JP2004528311A5 (ja) | ||
JPWO2021087136A5 (ja) | ||
JPWO2020103859A5 (ja) | ||
JP2009518393A5 (ja) | ||
JP2020533399A5 (ja) | ||
JP2020517731A5 (ja) |